DUBLIN--(BUSINESS WIRE)--The "Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029" report has been added to ResearchAndMarkets.com's offering.
Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body's immune system. Recent years have seen an increase in new therapies and the pipeline indicates this trend will continue. A large range of therapeutic areas from oncology to cardiology have seen rapidly proliferating clinical trials.
The report presents the market in segments that cover market estimates and forecasts, the development pipeline, and the competitive landscape of leading providers for each therapeutic area. It examines global developments in cell, gene, and RNA therapy markets for the select diseases and conditions in respective chapters, including principal products, trends in research and development, market breakdown of therapies, regional market revenues summary, and competitor summary.
The following therapeutic areas are covered:
- Oncology
- Neurology
- Musculoskeletal
- Dermatology
- Cardiology/non-oncology blood
- Other
Scope and Methodology
The report covers markets for cell therapies, gene therapies, and other various forms of RNA therapies.
The market segments provide highlights and overviews of therapies, market estimates and forecasts, and competitive situations of leading providers. The report also includes information on cell and gene therapies in development and the impact these are expected to have on the market. Throughout the report, several market indicators, trends, and barriers are discussed.
Because gene therapies are currently not available in any wide capacity, there is little precedent upon which to base forecasts. Dollar figures represent the estimated global market for 2023 and the expected market for 2029. Forecasts are provided through 2029, and the size of each market segment refers to manufacturers' revenues.
Key Topics Covered:
CHAPTER 1: EXECUTIVE SUMMARY
- Scope and Methodology
- Market Overview and Potential
CHAPTER 2: INTRODUCTION TO CELL AND GENE THERAPY
- Cell Therapy
- CAR T
- Stem Cells
- Adult Stem Cells
- Human Embryonic Stem Cells
- Gene Therapy
- Viral Vector System and New Developments
- Non-viral Systems for Transporting Genes
- Gene Editing
- Cell and Gene Therapy: Characteristics
- Staffing
- Manufacturing Process for CAR-T
- Leukapheresis
- Activation
- Transduction
- Expansion
- Cell and Gene Therapy Manufacturing Processes
- Cost
- Reimbursement
- Logistics
- Mergers and Acquisitions
- Deals, Agreements, and Collaborations
- Regulatory Developments
- Fast Track
- Orphan Drug
- Breakthrough Therapy
- Accelerated Approval
- Priority Review
- Individualized Gene Therapy Approval Process
- Pipeline, Development Overview
- Pipeline, Development Progress
- Pipeline by Condition and Therapeutic Area
- Phase III Development
- End Users
- Hospitals
- Research Institutes
- Wound Care Centers
- Cancer Centers
CHAPTER 3: CELL AND GENE THERAPY MARKETS IN ONCOLOGY
- Biochemistry of Cancer Cells
- Causes of Cancer Growth
- Environmental Factors, DNA, RNA
- Cellular Oncogenes
- Tumor Suppressor Genes
- Global Cancer Burden
- Market Outlook
-
Principal Products
- Abecma
- APCeden
- Breyanzi
- Carvykti
- CreaVax-RCC
- Delytact
- Gendicine
- Imlygic
- Immuncell-LC
- Kymriah
- Provenge
- Tecartus
- Yescarta
- Trends in Research and Development
- Phase III Development
- Market Breakdown of Cell and Gene Therapies
- Oncology Cell and Gene Therapy Market by Cancer Type
- Regional Market Summary
- Competitor Summary
CHAPTER 4: CELL AND GENE THERAPY MARKETS IN NEUROLOGICAL-RELATED DISORDERS
- Market Outlook
-
Principal Products
- Amvuttra
- Libmeldy/ Lenmeldy
- NeuroNata-R
- Onpattro
- SKYSONA
- Spinraza
- Stemirac
- Wainua
- Zolgensma
- Trends in Research and Development
- Phase III Development
- Market Breakdown of Cell and Gene Therapies
- Regional Market Summary
- Competitor Summary
CHAPTER 5: CELL AND GENE THERAPY MARKETS IN MUSCULOSKELETAL CONDITIONS AND DISORDERS
- Market Outlook
-
Principal Products
- AlloStem
- Amondys
- BIO4
- Carticel
- Cartiform
- CartiLife
- Cartistem
- Chondron
- Elevidys
- Exondys
- JACC
- MACI
- Ortho-ACI and Ortho-ATI
- Ossron
- Osteocel and Osteoplus
- Spherox
- Trinity Elite and Trinity Evolution
- Vyondys
- Trends in Research and Development
- Phase III Development
- Market Breakdown of Cell and Gene Therapies
- Musculoskeletal Cell and Gene Therapy Market by Indication
- Regional Market Summary
- Competitor Summary
CHAPTER 6: CELL AND GENE THERAPY MARKETS IN DERMATOLOGY
- Market Outlook
-
Principal Products
- Adipocel
- Apligraf
- CureSkin
- Dermagraft
- Epicel
- Grafix
- Holoderm
- Kaloderm
- KeraHeal/KeraHeal-Allo
- LaViv
- Orcel
- Quencell
- RECELL
- Rosmir
- Stempeutics/Cutisera
- StrataGraft
- Stravix
- TransCyte
- Vyjuvek
- Trends in Research and Development
- Phase III Development
- Market Breakdown of Cell and Gene Therapies
- Dermatology Cell and Gene Therapy Market by Indication
- Regional Market Summary
- Competitor Summary
CHAPTER 7: CELL AND GENE THERAPY MARKETS IN CARDIOVASCULAR AND BLOOD DISORDERS
- Cardiovascular Disease
- Selected Blood Disorders
- Market Outlook
-
Principal Products
- Collategene
- Hearticellgram
- HeartSheet
- Leqvio
- Neovasculgen
- Stempeucel
- Zynteglo
- Phase III Development
- Market Breakdown of Cell, Gene, and RNA Therapies
- Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
- Regional Market Summary
- Competitor Summary
CHAPTER 8: CELL AND GENE THERAPY MARKETS IN OTHER CONDITIONS
- Market Outlook
-
Principal Products
- Alofisel
- Cupistem
- Givlaari
- Glybera
- Holoclar
- Luxturna
- Oxlumo
- Rethymic
- Strimvelis
- Temcell/Prochymal/Ryoncil
- Trends in Research and Development
- Market Breakdown of Cell and Gene Therapies
- Regional Market Summary
- Competitor Summary
CHAPTER 9: CELL AND GENE THERAPY MARKET REVIEW
- Market Influences
- Global Demographics
- Aging Population
- Cost Containment
- Cell and Gene Therapy and Viral Vector Shortages
- Global Market Summary
- Cell vs. Gene Therapy Markets
- Regional Market Overview
- Competitor Ranking in Cell and Gene Therapy Markets
CHAPTER 10: MARKET PARTICIPANTS
- Leading Influencers
- AlloSource
- Alnylam Pharmaceuticals, Inc.
- Amgen
- AnGes Inc.
- Anterogen Co Ltd.
- Atara Biotherapeutics
- Athersys, Inc
- BioCardia
- Biogen, Inc.
- BioMarin Pharmaceuticals
- bluebird bio, Inc.
- BrainStorm Cell Therapeutics
- Bristol-Myers Squibb
- Candel Therapeutics
- Castle Creek Biosciences
- Celyad Oncology
- Cook Myosite, Inc
- Dendreon Pharmaceuticals (Sanpower)
- FerGene, Inc (Ferring Pharmaceuticals)
- Gamida Cell Ltd.
- GenSight Biologics S.A.
- Gilead Sciences, Inc.
- Gradalis, Inc
- Helixmith
- Inovio Pharmaceuticals, Inc.
- Kiadis Pharma B.V. (Sanofi)
- Medeor Therapeutics
- MEDIPOST Co, Ltd.
- MeiraGTx
- Mesoblast Ltd.
- Northwest Biotherapeutics, Inc.
- Novartis AG
- NuVasive Biologics
- Orchard Therapeutics
- Organogenesis
- Orthofix
- Osiris Therapeutics, Inc. (part of Smith & Nephew)
- Pharmicell
- Pluristem Therapeutics, Inc.
- Sangamo Therapeutics
- Sanofi
- Sarepta
- Sotio a.s.
- Spark Therapeutics
- Tessa Therapeutics, Ltd.
- uniQure N.V.
- Vericel
For more information about this report visit https://www.researchandmarkets.com/r/jte13a
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
